而一项刚刚发表在《柳叶刀》上的3期临床试验结果,为许多晚期难治性非小细胞肺癌(NSCLC)患者带来了好消息。 2023年7月6日,《柳叶刀》发表了一项题为:First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-contain...
Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR. Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology? Clin Lung Cancer. 2023 Jul;24...
Yeo JC, Takano A, Ong BH, Tan EH, Tan SH, Skanderup AJ, Tan DSW. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2022 Oct 20;178:
近日,一项来自中国台湾的回顾性研究评估了对EGFR-TKI治疗产生原发耐药的EGFR突变肺腺癌患者的PD-L1表达水平,研究结果刊登在Lung Cancer杂志上。 研究背景 肺癌是全世界癌症相关死亡的主要原因。根据分子生物学检测结果和组织学类型,肺癌的治疗越来越趋向个体化。EGFR突变是肺癌中最常见的驱动基因,在非小细胞肺癌(NSCLC)...
癌度与吉因加启动的“基因检测人人可及”公益计划,最低3000元检测肿瘤用药,您可以联系癌度咨询。 参考文献: Vamsidhar Velcheti, et al., Five-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥50% Advanced NSCLC, Clinical Lung Cancer (2024)....
Clin Lung Cancer. 2023 Jul;24(5):401-406. doi: 10.1016/j.cllc.2023.03.014. Epub 2023 Apr 25. PMID: 37208221.
[6] Perol, M., E. Felip, U. Dafni, et al., Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCL...
2019年8月在“Lung Cancer”上发表了一项全球、多中心、回顾性观察研究的结果。研究者从18个国家的45个中心中选择:年龄≥18岁、IIIB/IV期NSCLC、能收集到治疗前的肿瘤组织块(≤5年以内)的患者共2617例,使用PD-L1IHC22C3 pharmDx 试剂盒(Agilent, Santa Clara, CA, USA) 进行统一检测。
Clin Lung Cancer. 2023 Jul;24(5):401-406. doi: 10.1016/j.cllc.2023.03.014. Epub 2023 Apr 25. PMID: 37208221.
The success of immune checkpoint inhibitor therapy in lung cancer, both in squamous and nonsquamous non-small cell carcinoma, has led to US Food and Drug Administration approval for 2 medications that have as part of their...